Lipid nanoparticles improve activity of single-stranded siRNA and gapmer antisense oligonucleotides in animals

ACS Chemical Biology

Volumn 8, Issue 7, 2013, Pages 1402-1406

  Prakash, Thazha P ^a   Lima, Walt F ^a   Murray, Heather M ^a   Elbashir, Sayda ^b   Cantley, William ^b   Foster, Don ^b   Jayaraman, Muthusamy ^b   Chappell, Alfred E ^a   Manoharan, Muthiah ^b   Swayze, Eric E ^a   Crooke, Stanley T ^a  

^a ISIS PHARMACEUTICALS   (United States)

^b ALNYLAM PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5' VINYLPHOSPHONATE; ANTISENSE OLIGONUCLEOTIDE; MESSENGER RNA; PHOSPHATE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHONIC ACID DERIVATIVE; SINGLE STRANDED RNA; SINGLE STRANDED SMALL INTERFERING RNA; SMALL INTERFERING RNA; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; ENDOSOME; GENE SILENCING; HELA CELL; HUMAN; HUMAN CELL; IC 50; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA ANALYSIS; RNA INTERFERENCE;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HELA CELLS; HUMANS; INHIBITORY CONCENTRATION 50; LIPIDS; LIVER; MALE; MICE; MICE, INBRED BALB C; NANOPARTICLES; OLIGONUCLEOTIDES, ANTISENSE; PTEN PHOSPHOHYDROLASE; RNA, SMALL INTERFERING;

EID: 84880529654     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/cb4001316     Document Type: Article

References (30)

1. Crooke, S. T. (2008) Antisense Drug Technology Principles, Strategies, and Applications, 2nd ed., CRC Press Yaylor & Francis Group, 6000 Broken Sound Parkway NW, Suite 300, Boca Raton, FL.
2. Bumcrot, D., Manoharan, M., Koteliansky, V., and Sah, D. W. (2006) RNAi therapeutics: a potential new class of pharmaceutical drugs Nat. Chem. Biol. 2, 711-719
3. Whitehead, K. A., Langer, R., and Anderson, D.G.. (2009) Knocking down barriers: advances in siRNA delivery Nat. Rev. Drug Discovery 8, 129-138
4. Bennett, C. F. and Swayze, E. E. (2010) RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform Annu. Rev. Pharmacol. Toxicol. 50, 259-293
5. Liu, J., Carmell, M. A., Rivas, F. V., Marsden, C. G., Thomson, J. M., Song, J. J., Hammond, S. M., Joshua-Tor, L., and Hannon, G. J. (2004) Argonaute2 is the catalytic engine of mammalian RNAi Science 305, 1437-1441
6. Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., and Tuschl, T. (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells Nature 411, 494-498
7. Song, J. J., Smith, S. K., Hannon, G. J., and Joshua-Tor, L. (2004) Crystal structure of Argonaute and its implications for RISC slicer activity Science 305, 1434-1437
8. Rivas, F. V., Tolia, N. H., Song, J. J., Aragon, J. P., Liu, J., Hannon, G. J., and Joshua-Tor, L. (2005) Purified Argonaute2 and an siRNA form recombinant human RISC Nat. Struct. Mol. Biol. 12, 340-349
9. Lima, W. F., Prakash, T. P., Murray, H. M., Kinberger, G. A., Li, W., Chappell, A. E., Li, C. S., Murray, S. F., Gaus, H., Seth, P. P., Swayze, E. E., and Crooke, S. T. (2012) Single-stranded siRNAs activate RNAi in animals Cell 150, 883-894
10. Simberg, D., Weisman, S., Talmon, Y., and Barenholz, Y. (2004) DOTAP (and other cationic lipids): chemistry, biophysics, and transfection Crit. Rev. Ther. Drug Carrier Syst. 21, 257-317
11. Dass, C. R. (2004) Lipoplex-mediated delivery of nucleic acids: factors affecting in vivo transfection J. Mol. Med. 82, 579-591
12. Bakhtiyari, S., Haghani, K., Basati, G., and Karimfar, M. H. (2013) siRNA therapeutics in the treatment of diseases Ther. Delivery 4, 45-57
13. Akinc, A., Zumbuehl, A., Goldberg, M., Leshchiner, E. S., Busini, V., Hossain, N., Bacallado, S. A., Nguyen, D. N., Fuller, J., Alvarez, R., Borodovsky, A., Borland, T., Constien, R., de Fougerolles, A., Dorkin, J. R., Narayanannair Jayaprakash, K., Jayaraman, M., John, M., Koteliansky, V., Manoharan, M., Nechev, L., Qin, J., Racie, T., Raitcheva, D., Rajeev, K. G., Sah, D. W. Y., Soutschek, J., Toudjarska, I., Vornlocher, H.-P., Zimmermann, T. S., Langer, R., and Anderson, D. G. (2008) A combinatorial library of lipid-like materials for delivery of RNAi therapeutics Nat. Biotechnol. 26, 561-569
14. Jayaraman, M., Ansell, S. M., Mui, B. L., Tam, Y. K., Chen, J., Du, X., Butler, D., Eltepu, L., Matsuda, S., Narayanannair, J. K., Rajeev, K. G., Hafez, I. M., Akinc, A., Maier, M. A., Tracy, M. A., Cullis, P. R., Madden, T. D., Manoharan, M., and Hope, M. J. (2012) Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo Angew. Chem., Int. Ed. 51, 8529-8533
15. Semple, S. C., Akinc, A., Chen, J., Sandhu, A. P., Mui, B. L., Cho, C. K., Sah, D. W. Y., Stebbing, D., Crosley, E. J., Yaworski, E., Hafez, I. M., Dorkin, J. R., Qin, J., Lam, K., Rajeev, K. G., Wong, K. F., Jeffs, L. B., Nechev, L., Eisenhardt, M. L., Jayaraman, M., Kazem, M., Maier, M. A., Srinivasulu, M., Weinstein, M. J., Chen, Q., Alvarez, R., Barros, S. A., De, S., Klimuk, S. K., Borland, T., Kosovrasti, V., Cantley, W. L., Tam, Y. K., Manoharan, M., Ciufolini, M. A., Tracy, M. A., de Fougerolles, A., MacLachlan, I., Cullis, P. R., Madden, T. D., and Hope, M. J. (2010) Rational design of cationic lipids for siRNA delivery Nat. Biotechnol. 28, 172-176
16. Frank-Kamenetsky, M., Grefhorst, A., Anderson, N. N., Racie, T. S., Bramlage, B., Akinc, A., Butler, D., Charisse, K., Dorkin, R., Fan, Y., Gamba-Vitalo, C., Hadwiger, P., Jayaraman, M., John, M., Jayaprakash, K. N., Maier, M., Nechev, L., Rajeev, K. G., Read, T., Rohl, I., Soutschek, J., Tan, P., Wong, J., Wang, G., Zimmermann, T., de Fougerolles, A., Vornlocher, H. P., Langer, R., Anderson, D. G., Manoharan, M., Koteliansky, V., Horton, J. D., and Fitzgerald, K. (2008) Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates Proc. Natl. Acad. Sci. U.S.A. 105, 11915-11920
17. Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., Bigner, S. H., Giovanella, B. C., Ittmann, M., Tycko, B., Hibshoosh, H., Wigler, M. H., and Parsons, R. (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer Science 275, 1943-1947
18. Vickers, T. A., Koo, S., Bennett, C. F., Crooke, S. T., Dean, N. M., and Baker, B. F. (2003) Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents. A comparative analysis J. Biol. Chem. 278, 7108-7118
19. Prakash, T. P., Kawasaki, A. M., Wancewicz, E. V., Shen, L., Monia, B. P., Ross, B. S., Bhat, B., and Manoharan, M. (2008) Comparing in vitro and in vivo activity of 2′- O -[2-(methylamino)-2-oxoethyl]- and 2′-O-methoxyethyl-modified antisense oligonucleotides J. Med. Chem. 51, 2766-2776
20. Prakash, T. P., Allerson, C. R., Dande, P., Vickers, T. A., Sioufi, N., Jarres, R., Baker, B. F., Swayze, E. E., Griffey, R. H., and Bhat, B. (2005) Positional effect of chemical modifications on short interference RNA activity in mammalian cells J. Med. Chem. 48, 4247-4253
21. Vinciguerra, M. and Foti, M. (2008) PTEN at the crossroad of metabolic diseases and cancer in the liver Ann. Hepatol. 7, 192-199
22. Prakash, T. P., Allerson, C. R., Dande, P., Vickers, T. A., Sioufi, N., Jarres, R., Baker, B. F., Swayze, E. E., Griffey, R. H., and Bhat, B. (2005) Positional effect of chemical modifications on short interference RNA activity in mammalian cells J. Med. Chem. 48, 4247-4253
23. Prakash, T. P., Kawasaki, A. M., Wancewicz, E. V., Shen, L., Monia, B. P., Ross, B. S., Bhat, B., and Manoharan, M. (2008) Comparing in vitro and in vivo activity of 2′-O-[2-(methylamino)-2-oxoethyl]- and 2′-O-methoxyethyl-modified antisense oligonucleotides J. Med. Chem. 51, 2766-2776
24. Allerson, C. R., Sioufi, N., Jarres, R., Prakash, T. P., Naik, N., Berdeja, A., Wanders, L., Griffey, R. H., Swayze, E. E., and Bhat, B. (2005) Fully 2′-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA J. Med. Chem. 48, 901-904
25. Abrams, M. T., Koser, M. L., Seitzer, J., Williams, S. C., DiPietro, M. A., Wang, W., Shaw, A. W., Mao, X., Jadhav, V., Davide, J. P., Burke, P. A., Sachs, A. B., Stirdivant, S. M., and Sepp-Lorenzino, L. (2010) Evaluation of efficacy, biodistribution, and inflammation for a potent siRNA nanoparticle: effect of dexamethasone co-treatment Mol. Ther. 18, 171-180
26. De Fougerolles, A. V., H., P., and Maraganore, J. (2008) Lieberman Delivery vehicles for small interfering RNA in vivo Hum. Gene Ther. 19, 125-132
27. Vickers, T. A., Lima, W. F., Wu, H., Nichols, J. G., Linsley, P. S., and Crooke, S. T. (2009) Off-target and a portion of target-specific siRNA mediated mRNA degradation is Ago2 'Slicer' independent and can be mediated by Ago1 Nucleic Acids Res. 37, 6927-6941
28. Manoharan, M., Elbashir, S. M., Rajeev, K. G., Prakash, T. P., Lima, W. F., and Swayze, E. E. (2011) Lipid-formulated single-stranded antisense RNA compositions, p 185pp, (Isis Pharmaceuticals, Inc., USA; Alnylam Pharmaceuticals, Inc.). Application: WO 2011139911 A2 20111110.
29. Maurer, N., Wong, K. F., Stark, H., Louie, L., McIntosh, D., Wong, T., Scherrer, P., Semple, S. C., and Cullis, P. R. (2001) Spontaneous entrapment of polynucleotides upon electrostatic interaction with ethanol-destabilized cationic liposomes Biophys. J. 80, 2310-2326
30. Hashimoto, J. G., Beadles-Bohling, A. S., and Wiren, K. M. (2004) Comparison of RiboGreen and 18S rRNA quantitation for normalizing real-time RT-PCR expression analysis BioTechniques 36, 54-60